SCYNEXIS Company Profile (NASDAQ:SCYX)

About SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SCYX
  • CUSIP: N/A
  • Web: www.scynexis.com
Capitalization:
  • Market Cap: $53.15 million
  • Outstanding Shares: 26,722,000
Average Prices:
  • 50 Day Moving Avg: $2.21
  • 200 Day Moving Avg: $2.02
  • 52 Week Range: $1.52 - $4.21
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.85
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $256,999.00
  • Price / Sales: 207.95
  • Book Value: $1.20 per share
  • Price / Book: 1.67
Profitability:
  • EBITDA: ($25,040,000.00)
  • Net Margins: -9,648.47%
  • Return on Equity: -64.04%
  • Return on Assets: -37.19%
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 10.89%
  • Quick Ratio: 10.89%
Misc:
  • Average Volume: 256,188 shs.
  • Beta: 0.42
  • Short Ratio: 12.29
 

Frequently Asked Questions for SCYNEXIS (NASDAQ:SCYX)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings results on Monday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.04. The business earned $0.06 million during the quarter. SCYNEXIS had a negative net margin of 9,648.47% and a negative return on equity of 64.04%. View SCYNEXIS's Earnings History.

Where is SCYNEXIS's stock going? Where will SCYNEXIS's stock price be in 2017?

6 brokers have issued 1 year price objectives for SCYNEXIS's shares. Their forecasts range from $7.00 to $15.00. On average, they anticipate SCYNEXIS's stock price to reach $11.00 in the next year. View Analyst Ratings for SCYNEXIS.

What are analysts saying about SCYNEXIS stock?

Here are some recent quotes from research analysts about SCYNEXIS stock:

  • 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (10/10/2017)
  • 2. Guggenheim analysts commented, "Post 4Q16, we remain positive on SCYX because we believe SCY-078 still has a viable future and is differentiated as a potential IV-oral stepdown therapy for invasive fungal infections, an area of unmet need that is difficult to treat. While the delay in the IV formulation is not ideal, SCYX was not going to move forward with the high doses where the thrombotic events were experienced. SCYX will meet the FDA in 2Q17 to discuss a path forward for the IV formulation. Importantly, oral SCY-078 development is not affected, and SCYX continues to move forward with the rest of its pipeline assets as well." (3/14/2017)

Who are some of SCYNEXIS's key competitors?

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the folowing people:

  • Pamela J. Kirby Ph.D., Chairman of the Board
  • Marco Taglietti M.D., President, Chief Executive Officer, Director
  • Eric S. Francois, Chief Financial Officer
  • David Angulo M.D., Chief Medical Officer
  • Laurent Arthaud, Director
  • Steven C. Gilman Ph.D., Director
  • Ann F. Hanham Ph.D., Director
  • David C. Hastings, Director
  • Patrick J. Langlois Ph.D., Director

How do I buy SCYNEXIS stock?

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYNEXIS stock can currently be purchased for approximately $2.00.


MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  253
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for SCYNEXIS (NASDAQ:SCYX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $11.00 (450.00% upside)
Consensus Price Target History for SCYNEXIS (NASDAQ:SCYX)
Price Target History for SCYNEXIS (NASDAQ:SCYX)
Analysts' Ratings History for SCYNEXIS (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017HC WainwrightSet Price TargetBuy$14.00HighView Rating Details
8/7/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
5/30/2017AegisReiterated RatingBuyMediumView Rating Details
5/9/2017Needham & Company LLCDowngradeBuy -> HoldHighView Rating Details
3/14/2017GuggenheimReiterated RatingBuy$15.00HighView Rating Details
3/3/2017Royal Bank Of CanadaReiterated RatingOutperform$15.00 -> $11.00N/AView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy -> Strong-Buy$8.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for SCYNEXIS (NASDAQ:SCYX)
Earnings by Quarter for SCYNEXIS (NASDAQ:SCYX)
Earnings History by Quarter for SCYNEXIS (NASDAQ SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($0.52)($0.56)$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)$0.06 millionViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)$0.06 millionViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)$5.30 millionViewN/AView Earnings Details
11/13/2014($0.53)($0.45)$4.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SCYNEXIS (NASDAQ:SCYX)
Current Year EPS Consensus Estimate: $-1.17 EPS
Next Year EPS Consensus Estimate: $-1.08 EPS

Dividends

Dividend History for SCYNEXIS (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for SCYNEXIS (NASDAQ:SCYX)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 36.75%
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Institutional Ownership by Quarter for SCYNEXIS (NASDAQ:SCYX)
Insider Trades by Quarter for SCYNEXIS (NASDAQ:SCYX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2017Marco TagliettiCEOBuy10,000$2.23$22,300.00View SEC Filing  
8/23/2017Marco TagliettiCEOBuy5,000$1.85$9,250.00View SEC Filing  
8/15/2017Marco TagliettiCEOBuy10,000$1.61$16,100.00View SEC Filing  
8/11/2017Gonzalez David AnguloInsiderBuy10,000$1.55$15,500.00View SEC Filing  
6/21/2017David C HastingsDirectorBuy20,000$1.75$35,000.00View SEC Filing  
5/12/2017Gonzalez David AnguloInsiderBuy15,000$1.70$25,500.00View SEC Filing  
5/12/2017Marco TagliettiCEOBuy25,000$1.69$42,250.00View SEC Filing  
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.00View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.00View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.00View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for SCYNEXIS (NASDAQ:SCYX)
Latest Headlines for SCYNEXIS (NASDAQ:SCYX)
Source:
DateHeadline
americanbankingnews.com logoCritical Analysis: SCYNEXIS (SCYX) & Akorn (AKRX)
www.americanbankingnews.com - October 17 at 4:10 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - October 10 at 10:14 AM
nasdaq.com logoIn vivo and in vitro data show SCY-078's favorable profile and potential therapeutic benefit
www.nasdaq.com - October 7 at 8:21 AM
finance.yahoo.com logoSCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
finance.yahoo.com - October 6 at 9:04 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 7:16 PM
americanbankingnews.com logoContrasting Corium International (CORI) and SCYNEXIS (SCYX)
www.americanbankingnews.com - October 1 at 10:22 AM
nasdaq.com logoSCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 - Nasdaq
www.nasdaq.com - September 28 at 12:19 AM
globenewswire.com logoSCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
globenewswire.com - September 27 at 5:54 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) CEO Marco Taglietti Purchases 10,000 Shares
www.americanbankingnews.com - September 25 at 7:36 PM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : September 22, 2017
finance.yahoo.com - September 23 at 5:44 AM
seekingalpha.com logoSCYNEXIS (SCYX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 9:51 AM
finance.yahoo.com logoWhat Does SCYNEXIS Inc’s (SCYX) Share Price Indicate?
finance.yahoo.com - September 14 at 9:51 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 6 at 6:46 PM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM
finance.yahoo.com logoETFs with exposure to SCYNEXIS, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:32 AM
finance.yahoo.com logoSCYNEXIS to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 9:49 AM
finance.yahoo.com logoSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:23 AM
seekingalpha.com logoScynexis Q2 - Steady As She Goes - Seeking Alpha
seekingalpha.com - August 23 at 11:22 AM
americanbankingnews.com logoInsider Buying: SCYNEXIS, Inc. (SCYX) CEO Buys 10,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:24 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Given a $14.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 16 at 8:02 AM
globenewswire.com logo“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 4:26 PM
finance.yahoo.com logo“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
finance.yahoo.com - August 15 at 4:26 PM
globenewswire.com logoSCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 6:49 AM
finance.yahoo.com logoSCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
finance.yahoo.com - August 15 at 6:49 AM
americanbankingnews.com logoSCYNEXIS, Inc. (NASDAQ:SCYX) Insider Gonzalez David Angulo Purchases 10,000 Shares
www.americanbankingnews.com - August 15 at 12:16 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 12 at 6:38 PM
globenewswire.com logoSCYNEXIS Reports Second Quarter 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 7:19 AM
finance.yahoo.com logoSCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 9 at 7:19 AM
americanbankingnews.com logoRoth Capital Analysts Give SCYNEXIS Inc (NASDAQ:SCYX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 6:20 PM
globenewswire.com logoSCYNEXIS to Present at the Canaccord Genuity Growth Conference - GlobeNewswire (press release)
globenewswire.com - August 7 at 3:29 PM
feeds.benzinga.com logoSCYNEXIS to Present at the Canaccord Genuity Growth Conference
feeds.benzinga.com - August 7 at 10:25 AM
globenewswire.com logoSCYNEXIS Announces Initiation of Dosing in Phase 2 Study ... - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:01 AM
finance.yahoo.com logoSCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
finance.yahoo.com - August 4 at 8:01 AM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 6:56 PM
americanbankingnews.com logoSCYNEXIS, Inc. (SCYX) Coverage Initiated at Roth Capital
www.americanbankingnews.com - July 10 at 9:02 PM
streetinsider.com logoScynexis (SCYX) Publishes Data on In Vitro Activity of SCYNEXIS ... - StreetInsider.com
www.streetinsider.com - June 15 at 4:32 PM
nasdaq.com logoSCYNEXIS, Inc. to Participate in the 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 13 at 10:46 AM
seekingalpha.com logoScynexis: Another Buy Opportunity On The Recent Pullback - Seeking Alpha
seekingalpha.com - May 17 at 7:17 AM
seekingalpha.com logoScynexis: Time To Abandon Ship? - Seeking Alpha
seekingalpha.com - May 11 at 1:00 AM
marketbeat.com logoScynexis reports 1Q loss
marketbeat.com - May 8 at 4:53 PM
streetinsider.com logoScynexis (SCYX) Says Eight Data Presentations at ECCMID Showcase Broad Applicability of SCY-078 - StreetInsider.com
www.streetinsider.com - April 26 at 9:14 PM
seekingalpha.com logoSCYNEXIS (SCYX) ECCMID SCY-078 Scientific Data Presentation Conference Call - Slideshow
seekingalpha.com - April 26 at 4:13 PM
prnewswire.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100000 ... - PR Newswire (press release)
www.prnewswire.com - April 21 at 8:14 AM
bizjournals.com logoHow These Generic Drugs Stocks are Faring? -- Zynerba Pharma, Patheon, SCYNEXIS, and Flexion Therapeutics
www.bizjournals.com - April 11 at 9:47 AM
us.rd.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - April 4 at 12:22 AM
us.rd.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 31 at 7:56 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against SCYNEXIS, Inc. (SCYX) and Lead Plaintiff Deadline - May 8, 2017
us.rd.yahoo.com - March 30 at 7:59 PM
businesswire.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In SCYNEXIS, Inc. To Contact Brower Piven Before The Lead Plaintiff ...
www.businesswire.com - March 28 at 9:28 AM
us.rd.yahoo.com logoSCYX INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017
us.rd.yahoo.com - March 24 at 7:34 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline – SCYX
us.rd.yahoo.com - March 24 at 7:34 PM

Social

Chart

SCYNEXIS (SCYX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.